


ddPCR™ Microsatellite Instability (MSI) Kit

Simple, Automated Sample Analysis with Tissue and Plasma Samples



Microsatellite instability (MSI) creates a state of genetic hypermutability due to compromised mismatch repair (MMR). This results in the generation of short tandem DNA repeat sequences throughout the genome. MSI is associated with an increasing number of cancers and is a critical biomarker for immune checkpoint inhibitor research and therapies.

Bio-Rad's cutting-edge MSI kit uses Droplet Digital™ PCR (ddPCR) technology for sensitive, reproducible, and rapid assessment of five key MSI markers. The ddPCR MSI Assay can be used to analyze formalin-fixed paraffin-embedded (FFPE) samples without the need for normal tissue, as well as circulating tumor DNA (ctDNA) from plasma, reducing the need for invasive biopsies. The ability to leverage the same assay and the QX200™ Droplet Digital PCR System for both FFPE and plasma, combined with the capacity to complete testing in as little as 1 day, enables expedited answers and reflex testing. Bio-Rad's ddPCR MSI Kit has the speed, sensitivity, and reproducibility to meet your laboratory MSI testing needs.











Sensitive and Specific

100% Sensitivity96% Specificity

Independent study using FFPE compared to PCR-CE.

Minimal Input Required

2 ng/10%

Obtain accurate results with minimal input and tumor content.

Data in Less Than 6 Hours



Obtain a full plate of results from DNA for all five markers in ~5.5 hours.

MSI Kit Concordance in Both CRC and Non-CRC Cancers

Site	Sample Type	Diagnosis	Number	MSI-H	MSS	MSI Status Concordance, %	Original Methods
1	FFPE	CRC	10	5	5	100	PCR-CE
	Plasma	CRC	8	2*	6	87.5	PCR-CE (matched tissue)
2	FFPE	CRC	10	5	5	100	IHC and PCR-melt
	Plasma	CRC	38	1	37	100	IHC and PCR-melt (matched tissue)
3	FFPE	CRC	16	9	7	100	PCR-CE
	FFPE	Non-CRC**	12	3***	9†	100	IHC and PCR-CE

Across three sites, MSI performance was compared to original methods, displaying high concordance for both CRC and non-CRC samples.

IHC, immunohistochemistry; MSI-H, microsatellite instability high; MSS, microsatellite stable; PCR-CE, polymerase chain reaction-capillary electrophoresis.

- * Low input nucleic acid (0.53 ng instead of nominal 2.6 ng) may explain the discordance in this ddPCR result.
- ** Non-CRC samples included endometrial, adrenal, metastatic cervical, prostate, pancreatic, duodenal, gall bladder, esophageal, lung, and gastric cancer tissue.
- *** MSI-H adrenal sample not detected by PCR-CE.
- † BAT26 detected by Droplet Digital PCR but not detected by PCR-CE for pancreatic and esophageal samples.

The ddPCR Microsatellite Instability (MSI) Kit includes:

- ddPCR Multiplex Supermix (2 aliquots)
- ddPCR MSI Assay 1 (BAT25/BAT26)
- ddPCR MSI Assay 2 (NR21/NR24)
- ddPCR MSI Assay 3 (MONO27)
- ddPCR Positive Control
- Uracil-DNA Glycosylase (UDG)
- Nuclease-Free Water (2 aliquots)

Ordering Information

Catalog # Description

12015172 ddPCR Microsatellite Instability (MSI) Kit

Visit bio-rad.com/ddPCR-MSI for more information.

For research use only. Not for use in diagnostic procedures.



BIO-RAD, DROPLET DIGITAL, DDPCR, and QX200 are trademarks of Bio-Rad Laboratories, Inc. in certain jurisdictions. All trademarks used herein are the property of their respective owner. © 2023 Bio-Rad Laboratories, Inc.

Purchase of Digital PCR and/or Single-Cell NGS Sample Preparation products (the "Products") from Bio-Rad Laboratories is subject to Bio-Rad Laboratories, Inc. Standard Terms and Conditions of Sale, which can be accessed at https://www.bio-rad.com/en-us/terms-conditions. Unless we expressly state otherwise in additional Terms and Conditions, no rights are granted for you to distribute or resell the Products. Unless we expressly state otherwise in additional Terms and Conditions, no rights are granted for the development or commercialization of diagnostic assays for use with the Products without a license from Bio-Rad. It is the user's obligation to obtain a commercial license from Bio-Rad for (i) all commercial uses (not just diagnostic uses) and (ii) sale of assays for use on Bio-Rad's dPCR and ddSEQ instruments. The Products and/or their use are covered by U.S. and foreign patents and/or pending patent applications owned by or under license to Bio-Rad Laboratories, Inc. See https://www.bio-rad.com/en-us/trademarks.



Bio-Rad Laboratories, Inc.

Life Science Group Website bio-rad.com USA 1 800 424 6723 Australia 61 2 9914 2800 Austria 00 800 00 24 67 23 Belgium 00 800 00 24 67 23 Brazil 4003 0399 Canada 1 905 364 3435 China 86 21 6169 8500 Czech Republic 00 800 00 24 67 23 Denmark 00 800 00 24 67 23 Finland 00 800 00 24 67 23 France 00 800 00 24 67 23 Germany 00 800 00 24 67 23 Hong Kong 852 2789 3300 Hungary 00 800 00 24 67 23 India 91 124 4029300 Israel 0 3 9636050 Italy 00 800 00 24 67 23 Japan 81 3 6361 7000 Korea 82 080 007 7373 Luxembourg 00 800 00 24 67 23 Mexico 52 555 488 7670

The Netherlands 00 800 00 24 67 23 New Zealand 64 9 415 2280 Norway 00 800 00 24 67 23 Portugal 00 800 00 24 67 23 Russian Federation 00 800 00 24 67 23 Singapore 65 6415 3188 South Africa 00 800 00 02 46 723 Spain 00 800 00 24 67 23 Sweden 00 800 00 24 67 23 Sweden 00 800 00 24 67 23 Taiwan 886 2 2578 7189 Thailand 66 2 651 8311 United Arab Emirates 36 1 459 6150 United Kingdom 00 800 00 24 67 23

Bulletin 3532 Ver A US/EG 23-0483 0623 Sig 0123

